Deborah Chandler
Nurse Practitioner · Orlando, FLNPI 1861696247
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. EMD Serono, Inc. accounts for 77.2% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2021 at $27,783 and has fallen 85.5% since, to $4,029 in 2025. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $156.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$46K
- Sanofi$4K
- Johnson & Johnson$3K
- Genentech USA, Inc.$810
- Biogen$810
- Bristol Myers Squibb$630
- plus $4K from 25 others
What the payments were for
- Consulting fees$11,71619%
- Speaking & faculty fees$34,40057%
- Travel & lodging$4,9158%
- Food & beverage$8,94615%
- Education$1810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 72 | $46,414 |
| Sanofi | 26 | $4,143 |
| Johnson & Johnson | 11 | $3,375 |
| Genentech USA, Inc. | 40 | $810 |
| Biogen | 35 | $810 |
| Bristol Myers Squibb | 23 | $630 |
| Amgen(2 entities) | 15 | $623 |
| Eisai Inc. | 14 | $551 |
| Novartis | 59 | $523 |
| AstraZeneca | 12 | $422 |
| AbbVie(2 entities) | 18 | $382 |
| Lilly USA, LLC | 15 | $339 |
| E.r. Squibb & Sons, L.L.C. | 2 | $196 |
| Tanabe Pharma America, Inc. | 10 | $160 |
| Abbott | 1 | $127 |
| Banner Life Sciences, LLC | 8 | $126 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Biohaven Pharmaceuticals, Inc. | 4 | $78 |
| Sanofi-aventis U.S. LLC | 2 | $72 |
| Avanir Pharmaceuticals, Inc. | 3 | $48 |
| Heron Therapeutics, Inc. | 1 | $46 |
| Cala Health, Inc. | 1 | $39 |
| UCB, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| TG Therapeutics, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Argenx US, Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,159 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 22 | $190,804 |
| TecfideraDimethyl Fumarate | 13 | $115,416 |
| RexultiBrexpiprazole | 24 | $51,106 |
| Memantine Hcl | 266 | $9,113 |
| RivastigmineRivastigmine Tartrate | 51 | $3,167 |
| Rivastigmine | 20 | $2,869 |
| Donepezil Hcl | 202 | $2,324 |
| Quetiapine Fumarate | 42 | $739 |
| Escitalopram Oxalate | 62 | $690 |
| Duloxetine Hcl | 18 | $609 |
| Gabapentin | 22 | $300 |
| Buspirone Hcl | 28 | $227 |
| Trazodone Hcl | 40 | $175 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $136 |
| Diazepam | 24 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tecfidera | $810 | $306,22035 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $80 | $51,10624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Orlando
- Jason RoyOrlando$95K
- Jennifer BlattnerOrlando$24K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.